Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Daito Pharmaceutical Co., Ltd. ( (JP:4577) ) has issued an announcement.
Daito Pharmaceutical Co., Ltd., a Japan-based pharmaceutical company listed on the Prime Market of the Tokyo Stock Exchange, focuses on developing and providing pharmaceutical and healthcare products. The company announced that it has identified errors in its “Second Half, Fiscal Year Ending May 2026 Financial Results Presentation Materials” released on January 14, 2026, and will partially correct them, updating the version posted on its website accordingly; although the specific corrections were not disclosed in this notice, the move reflects an effort to ensure the accuracy and reliability of its financial disclosures for investors and other stakeholders.
The most recent analyst rating on (JP:4577) stock is a Hold with a Yen1442.00 price target. To see the full list of analyst forecasts on Daito Pharmaceutical Co., Ltd. stock, see the JP:4577 Stock Forecast page.
More about Daito Pharmaceutical Co., Ltd.
Daito Pharmaceutical Co., Ltd. is a Japan-based pharmaceutical company listed on the Prime Market of the Tokyo Stock Exchange (securities code 4577), engaged in the development and sale of pharmaceutical products and related healthcare offerings.
Average Trading Volume: 64,247
Technical Sentiment Signal: Buy
Current Market Cap: Yen40.62B
Learn more about 4577 stock on TipRanks’ Stock Analysis page.